{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:14:01Z","timestamp":1787242441707,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["RE\/24\/130035"],"award-info":[{"award-number":["RE\/24\/130035"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["CH\/1999001\/11735"],"award-info":[{"award-number":["CH\/1999001\/11735"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["PG\/22\/11055"],"award-info":[{"award-number":["PG\/22\/11055"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Physiol Biochem"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The interplay between systolic and diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF) progression is unclear. First-phase ejection fraction (EF1), a sensitive marker of early systolic function, aids in assessing systolic-diastolic relationships in human hypertension and aortic stenosis. This study examines temporal changes in these relationships in mouse models of HFpEF and elevated afterload. Mouse models of abdominal aortic banding (AAB) and HFpEF (induced by hypertension and high fat feeding) underwent comprehensive serial echocardiography. In AAB, EF1 significantly decreased at week 1 post-surgery (18.8 \u00b1 1.2 vs 24.3 \u00b1 0.8%, p&lt;0.001) compared to controls, with further reduction at week 3 (16.8 \u00b1 0.6%) and week 6 (13.9 \u00b1 0.9%, both p&lt;0.001). EF, global longitudinal strain (GLS) and longitudinal strain rate (LSR) remained unchanged until week 3. Isovolumic relaxation time (IVRT) was the only abnormal index of diastolic function at week 1. In the HFpEF model, EF1 significantly decreased at week 2 (19.1 \u00b1 1.1 vs 25.8 \u00b1 1.0%, p&lt;0.001) compared to controls, while EF, GLS, and LSR were unaltered. At week 3, EF1 decreased further (18.1 \u00b1 0.7%) alongside a significant reduction in GLS (p&lt;0.01), while EF and LSR remained unchanged. IVRT increased early in the HFpEF model, followed by later left atrial (LA) enlargement. EF1, an early marker of systolic impairment, decreases early in HFpEF and afterload-induced dysfunction, accompanied by IVRT prolongation. LA dilatation appears later. These findings highlight the interplay between systolic and diastolic dysfunction in HFpEF progression.<\/jats:p>","DOI":"10.1007\/s13105-026-01138-6","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:29:32Z","timestamp":1770182972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temporal changes in first-phase ejection fraction during evolution of heart failure with preserved ejection fraction and afterload-induced heart failure in mice"],"prefix":"10.1007","volume":"82","author":[{"given":"Haotian","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Catibog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asjad","family":"Visnagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Chowienczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1657-1337","authenticated-orcid":false,"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"1138_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00540-y","volume":"10","author":"CE Hamo","year":"2024","unstructured":"Hamo CE, DeJong C, Hartshorne-Evans N, Lund LH, Shah SJ, Solomon S, Lam CSP (2024) Heart failure with preserved ejection fraction. Nat Rev Dis Primers 10:55. https:\/\/doi.org\/10.1038\/s41572-024-00540-y","journal-title":"Nat Rev Dis Primers"},{"key":"1138_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcmg.2018.12.034","volume":"13","author":"M Obokata","year":"2020","unstructured":"Obokata M, Reddy YNV, Borlaug BA (2020) Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods. JACC Cardiovasc Imaging 13:245\u2013257. https:\/\/doi.org\/10.1016\/j.jcmg.2018.12.034","journal-title":"JACC Cardiovasc Imaging"},{"key":"1138_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08545","author":"H Gu","year":"2017","unstructured":"Gu H, Li Y, Fok H, Simpson J, Kentish JC, Shah AM, Chowienczyk PJ (2017) Reduced first-phase ejection fraction and sustained myocardial wall stress in hypertensive patients with diastolic dysfunction: a manifestation of impaired shortening deactivation that links systolic to diastolic dysfunction and preserves systolic ejection fraction. Hypertension. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08545","journal-title":"Hypertension"},{"key":"1138_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jcmg.2018.08.037","volume":"12","author":"H Gu","year":"2019","unstructured":"Gu H, Saeed S, Boguslavskyi A, Carr-White G, Chambers JB, Chowienczyk P (2019) First-phase ejection fraction is a powerful predictor of adverse events in asymptomatic patients with aortic stenosis and preserved total ejection fraction. JACC Cardiovasc Imaging 12:52\u201363. https:\/\/doi.org\/10.1016\/j.jcmg.2018.08.037","journal-title":"JACC Cardiovasc Imaging"},{"key":"1138_CR5","first-page":"1410","volume":"24","author":"AJ Brady","year":"1965","unstructured":"Brady AJ (1965) Time and displacement dependence of cardiac contractility: problems in defining the active state and force-velocity relations. Fed Proc 24:1410\u20131420","journal-title":"Fed Proc"},{"key":"1138_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1113\/jphysiol.1978.sp012513","volume":"283","author":"DL Brutsaert","year":"1978","unstructured":"Brutsaert DL, de Clerck NM, Goethals MA, Housmans PR (1978) Relaxation of ventricular cardiac muscle. J Physiol 283:469\u2013480","journal-title":"J Physiol"},{"key":"1138_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1126\/science.6857274","volume":"221","author":"PR Housmans","year":"1983","unstructured":"Housmans PR, Lee NK, Blinks JR (1983) Active shortening retards the decline of the intracellular calcium transient in mammalian heart muscle. Science 221:159\u2013161","journal-title":"Science"},{"key":"1138_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nature15727","volume":"528","author":"M Linari","year":"2015","unstructured":"Linari M, Brunello E, Reconditi M, Fusi L, Caremani M, Narayanan T, Piazzesi G, Lombardi V, Irving M (2015) Force generation by skeletal muscle is controlled by mechanosensing in myosin filaments. Nature 528:276\u2013279. https:\/\/doi.org\/10.1038\/nature15727","journal-title":"Nature"},{"key":"1138_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.yjmcc.2017.10.006","volume":"114","author":"M Schnelle","year":"2018","unstructured":"Schnelle M, Catibog N, Zhang M, Nabeebaccus AA, Anderson G, Richards DA, Sawyer G, Zhang X, Toischer K, Hasenfuss G et al (2018) Echocardiographic evaluation of diastolic function in mouse models of heart disease. J Mol Cell Cardiol 114:20\u201328. https:\/\/doi.org\/10.1016\/j.yjmcc.2017.10.006","journal-title":"J Mol Cell Cardiol"},{"key":"1138_CR10","doi-asserted-by":"publisher","first-page":"R1597","DOI":"10.1152\/ajpregu.00825.2009","volume":"298","author":"D Fliegner","year":"2010","unstructured":"Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek E, Staub E, Martus P, Ruiz Noppinger P, Kintscher U et al (2010) Female sex and Estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 298:R1597\u20131606. https:\/\/doi.org\/10.1152\/ajpregu.00825.2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1138_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1161\/HYPERTENSIONAHA.107.107938","volume":"51","author":"A Karatas","year":"2008","unstructured":"Karatas A, Hegner B, de Windt LJ, Luft FC, Schubert C, Gross V, Akashi YJ, Gurgen D, Kintscher U, da Costa Goncalves AC et al (2008) Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. Hypertension 51:1177\u20131183. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.107938","journal-title":"Hypertension"},{"key":"1138_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/cvr\/cvu182","volume":"104","author":"A Boguslavskyi","year":"2014","unstructured":"Boguslavskyi A, Pavlovic D, Aughton K, Clark JE, Howie J, Fuller W, Shattock MJ (2014) Cardiac hypertrophy in mice expressing unphosphorylatable phospholemman. Cardiovasc Res 104:72\u201382. https:\/\/doi.org\/10.1093\/cvr\/cvu182","journal-title":"Cardiovasc Res"},{"key":"1138_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/cvr\/cvx204","volume":"114","author":"M Zhang","year":"2018","unstructured":"Zhang M, Mongue-Din H, Martin D, Catibog N, Smyrnias I, Zhang X, Yu B, Wang M, Brandes RP, Schr\u00f6der K et al (2018) Both cardiomyocyte and endothelial cell Nox4 mediate protection against hemodynamic overload-induced remodelling. Cardiovasc Res 114:401\u2013408. https:\/\/doi.org\/10.1093\/cvr\/cvx204","journal-title":"Cardiovasc Res"},{"key":"1138_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jacbts.2017.07.013","volume":"2","author":"M Valero-Mu\u00f1oz","year":"2017","unstructured":"Valero-Mu\u00f1oz M, Backman W, Sam F (2017) Murine models of heart failure with preserved ejection fraction. JACC: Basic Translational Sci 2:770\u2013789. https:\/\/doi.org\/10.1016\/j.jacbts.2017.07.013","journal-title":"JACC: Basic Translational Sci"},{"key":"1138_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/CIRCULATIONAHA.109.883777","volume":"121","author":"GA Silberman","year":"2010","unstructured":"Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE et al (2010) Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 121:519\u2013528","journal-title":"Circulation"},{"key":"1138_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jacc.2015.05.020","volume":"66","author":"M Zhang","year":"2015","unstructured":"Zhang M, Prosser BL, Bamboye MA, Gondim ANS, Santos CX, Martin D, Ghigo A, Perino A, Brewer AC, Ward CW et al (2015) Contractile function during Angiotensin-II activation: increased Nox2 activity modulates cardiac calcium handling via phospholamban phosphorylation. J Am Coll Cardiol 66:261\u2013272","journal-title":"J Am Coll Cardiol"},{"key":"1138_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/01.CIR.94.5.1109","volume":"94","author":"N Tanaka","year":"1996","unstructured":"Tanaka N, Dalton N, Mao L, Rockman HA, Peterson KL, Gottshall KR, Hunter JJ, Chien KR, Ross J (1996) Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 94:1109\u20131117. https:\/\/doi.org\/10.1161\/01.CIR.94.5.1109","journal-title":"Circulation"},{"key":"1138_CR18","doi-asserted-by":"publisher","first-page":"H1371","DOI":"10.1152\/ajpheart.00553.2013","volume":"306","author":"A Bhan","year":"2014","unstructured":"Bhan A, Sirker A, Zhang J, Protti A, Catibog N, Driver W, Botnar R, Monaghan MJ, Shah AM (2014) High-frequency speckle tracking echocardiography in the assessment of left ventricular function and remodeling after murine myocardial infarction. Am J Physiol Heart Circ Physiol 306:H1371\u2013H1383","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1138_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/01.cir.29.2.268","volume":"29","author":"RF Rushmer","year":"1964","unstructured":"Rushmer RF (1964) Initial ventricular impulse. A potential key to cardiac evaluation. Circulation 29:268\u2013283. https:\/\/doi.org\/10.1161\/01.cir.29.2.268","journal-title":"Circulation"},{"key":"1138_CR20","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/eurheartj\/ehad884","volume":"45","author":"R Wang","year":"2024","unstructured":"Wang R, Schiattarella GG (2024) Tackling metabolic defects in HFpEF. Eur Heart J 45:1494\u20131496. https:\/\/doi.org\/10.1093\/eurheartj\/ehad884","journal-title":"Eur Heart J"},{"key":"1138_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCRESAHA.119.315891","volume":"126","author":"DA Eisner","year":"2020","unstructured":"Eisner DA, Caldwell JL, Trafford AW, Hutchings DC (2020) The control of diastolic calcium in the heart. Circ Res 126:395\u2013412. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.315891","journal-title":"Circ Res"},{"key":"1138_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/heartjnl-2020-316684","volume":"106","author":"R Bing","year":"2020","unstructured":"Bing R, Gu H, Chin C, Fang L, White A, Everett RJ, Spath NB, Park E, Jenkins WS, Shah AS et al (2020) Determinants and prognostic value of echocardiographic first-phase ejection fraction in aortic stenosis. Heart 106:1236\u20131243. https:\/\/doi.org\/10.1136\/heartjnl-2020-316684","journal-title":"Heart"},{"key":"1138_CR23","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1161\/HYPERTENSIONAHA.121.17099","volume":"77","author":"H Gu","year":"2021","unstructured":"Gu H, Cirillo C, Nabeebaccus AA, Sun Z, Fang L, Xie Y, Demir O, Desai N, He L, Lu Q et al (2021) First-phase ejection fraction, a measure of preclinical heart failure, is strongly associated with increased mortality in patients with COVID-19. Hypertension 77:2014\u20132022. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17099","journal-title":"Hypertension"},{"key":"1138_CR24","doi-asserted-by":"publisher","unstructured":"Sun Z, Cai Y, Yang Y, Huang L, Xie Y, Zhu S, Wu C, Sun W, Zhang Z, Li Y et al (2023) Early left ventricular systolic function is a more sensitive predictor of adverse events after heart transplant. Int J Cardiol 131620. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131620","DOI":"10.1016\/j.ijcard.2023.131620"},{"key":"1138_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030868","author":"A Minczykowski","year":"2023","unstructured":"Minczykowski A, Zwanzig M, Dziarmaga M, Rutkowska A, Bali\u0144ski M, Krauze T, Guzik P, Wykr\u0119towicz A (2023) First-phase left ventricular ejection fraction as an early sign of left ventricular dysfunction in patients with stable coronary artery disease. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12030868","journal-title":"J Clin Med"},{"key":"1138_CR26","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.jcmg.2021.05.007","volume":"14","author":"H Gu","year":"2021","unstructured":"Gu H, Sidhu BS, Fang L, Webb J, Jackson T, Claridge S, Einarsen E, Razavi R, Papageorgiou N, Chow A et al (2021) First-phase ejection fraction predicts response to cardiac resynchronization therapy and adverse outcomes. JACC Cardiovasc Imaging 14:2275\u20132285. https:\/\/doi.org\/10.1016\/j.jcmg.2021.05.007","journal-title":"JACC Cardiovasc Imaging"},{"key":"1138_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-021-00756-x","volume":"23","author":"H Gu","year":"2021","unstructured":"Gu H, Bing R, Chin C, Fang L, White AC, Everett R, Spath N, Park E, Chambers JB, Newby DE et al (2021) First-phase ejection fraction by cardiovascular magnetic resonance predicts outcomes in aortic stenosis. J Cardiovasc Magn Reson 23:73. https:\/\/doi.org\/10.1186\/s12968-021-00756-x","journal-title":"J Cardiovasc Magn Reson"}],"container-title":["Journal of Physiology and Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-026-01138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13105-026-01138-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-026-01138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:29:33Z","timestamp":1770182973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13105-026-01138-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s13105-026-01138-6","relation":{},"ISSN":["1138-7548","1877-8755"],"issn-type":[{"value":"1138-7548","type":"print"},{"value":"1877-8755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HG and PC are named on a patent of EF1. AMS is a Board advisor to Forcefield Therapeutics and Heqet Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}